Latest Comments

NICE: too nice for too long?

NICE: too nice for too long?

Novel Approaches to US Cancer Research Funding on the Horizon

Novel Approaches to US Cancer Research Funding on the Horizon

U-turn: life-prolonging breast cancer drug now available on the NHS

U-turn: life-prolonging breast cancer drug now available on the NHS

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

Rule-breakers: rehabilitating wayward clinical researchers

Rule-breakers: rehabilitating wayward clinical researchers

Could copper unlock a new wave of metabolic treatments?

Could copper unlock a new wave of metabolic treatments?